PTK2 and melanoma: As the FAK inhibitor, VS-6063 [49], and the MEK-1 inhibitor, PD98059 [50], impair the androgen-triggered motility in wound scratch assay (Fig. 8D, E), we concluded that the androgen/AR axis engages and activates the two effectors to drive melanoma cell locomotion.